Evidence map›Paper›PMID 40459724›Full record

ReviewProbiotics and antimicrobial proteins2025

A Review of Next-Generation Probiotics-As a Gateway to Biotherapeutics.

A Vijayaganapathi, V Mohanasrinivasan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Pharmaceutics · 2025
    Article
  9. Molecular Mechanisms of Probiotic Action Against Gastrointestinal Cancers.International journal of molecular sciences · 2025
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

A VijayaganapathiSchool of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India.
V MohanasrinivasanSchool of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India. v.mohan@vit.ac.in.ORCID 0009-0005-6148-5210

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Next-generation probiotics (NGPs) represent a promising advancement in microbial therapeutics, offering targeted and personalized interventions for various health disorders. Unlike traditional probiotics, NGPs focus on specific bacterial strains with enhanced functional properties, achieved through genetic engineering and next-generation sequencing technologies. Their applications span gastrointestinal disorders, metabolic syndromes, immune-related conditions, skin diseases, oral health, and animal well-being. NGPs contribute to gut microbiome modulation, metabolic regulation, and immune system enhancement, demonstrating therapeutic potential in clinical studies. Regulatory challenges persist, as NGPs fall under different legal classifications worldwide, necessitating rigorous safety assessments, including whole-genome sequencing to evaluate virulence and antibiotic resistance. Clinical trials continue to validate their efficacy in diverse conditions, emphasizing the need for standardized guidelines. Furthermore, novel probiotic delivery systems, including microdevices and targeted coatings, are being explored to improve bacterial viability and colonization in the gut. Identifying new probiotic strains with enhanced survival capabilities and elucidating their mechanisms of action remain critical for advancing probiotic science. Cost-effectiveness and commercialization of NGPs present opportunities for broader healthcare integration, with increasing research supporting their role in disease prevention and treatment. This review highlights the multifaceted potential of NGPs and the challenges that must be addressed for their successful implementation in modern healthcare.

Indexed as

ProbioticsAnimalsGastrointestinal MicrobiomeHumansBiotherapeuticsMicroencapsulationNext-generation probioticsProbioticsSynbiotics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.